Russia’s focus on domestic pharma production could shield it from sanctions’ effects
Russia’s pharma manufacturing is more focused on the domestic market due to its comparative lack of FDA and EMA approvals.
By
Russia’s pharma manufacturing is more focused on the domestic market due to its comparative lack of FDA and EMA approvals.
By GlobalData HealthcarePackaging is creating bottlenecks in producing injectable drugs, as the industry lacks the capacity to make and fill enough…
By GlobalData HealthcareOxurion has announced that clinical trials for THR-687, its novel pharmacotherapy for diabetic macular oedema, will not continue.
By GlobalData HealthcareThe UK’s National Institute for Health and Care Excellence (NICE) has endorsed the Sleepio digital therapeutic to treat insomnia.
By GlobalData HealthcareRecent advancements in late-stage therapies for geographic atrophy have raised hopes of ushering in its first wave of therapies.
By GlobalData HealthcareThe alpha-1 antitrypsin deficiency (AATD) market in the US and Germany is expected to see significant growth from 2021…
By GlobalData HealthcareConventional analgesics prescribed for osteoarthritis offer inadequate pain relief and are associated with several adverse events.
By GlobalData HealthcareThe US FDA has rejected a new drug application (NDA) from HUTCHMED for surufatinib for advanced neuroendocrine tumours (NETs).
By GlobalData HealthcareTislelizumab has been making strides towards approval for the treatment of second-line oesophagal squamous cell carcinoma (ESCC).
By GlobalData HealthcareThank you for subscribing to Pharmaceutical Technology